Summit Therapeutics Inc.’s SMMT share price has surged by 6.58%, which has investors questioning if this is right time to ...

Hong Kong-based Akeso has announced that the US Food and Drug Administration (FDA) has approved its PD-1 monoclonal antibody, penpulimab-kcqx, alongside cisplatin or carboplatin and gemcitabine, for ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

Summit Therapeutics Inc. is currently enrolling patients in the Harmoni-7 study, a multiregional Phase III clinical trial ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

There was HKD2 billion, HKD779 million and HKD556.9 million Southbound Trading net inflow to TRACKER FUND (02800.HK), AKESO ...

Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

The U.S. Food and Drug Administration this week granted permission for the use of a new cancer drug from China despite ...

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...